Roche Holding AG is considering options for its diabetes-care business including a sale, Bloomberg reported, citing people familiar with the matter.
The alternatives for the unit could include a partial sale or spinoff and the sale could fetch as much as $5 billion, Bloomberg also reported.
The Swiss drugmaker had said last year that it has no plans to sells its diabetes testing business.
Johnson & Johnson said last week that it is looking to divest its diabetes division, while Bayer AG sold its diabetes business to KKR and Panasonic in 2015, for $1.1 billion.
Roche was not immediately available for comment outside regular business hours.
By Parikshit Mishra
Source: Reuters
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.